Dexamthsone

PreclinicalSmall molecule

UUniversity of Chicago

Dexamthsone is one of 28 small molecule programs targeting Dexamethasone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DexamethasoneTerminated

DexamethasonePreclinical

Terminated

Competition

Competitive Landscape

33 competitors in Dexamethasone

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Rayos

3 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

17 4

Empliciti

Bristol-Myers Squibb

Phase 3

2 5

Velcade

SShilpa Grover, MD, MPH

Phase 3

9 6

Kyprolis

VVirionyx Corporation Limited

Phase 3

6 7

Zyprexa

MMODAG GmbH

Phase 3

3 8

Decadron

QQuince Therapeutics S.p.A.

Phase 3

3 9

Darzalex

Johnson & Johnson

Phase 2

5 10

Ninlaro

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dexamethasone1 trial

Dexamethasone and Block Duration in Upper Extremity

Terminated·UUniversity of Chicago·N/A·NCT01756573·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dexamthsone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamthsone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamthsone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Chicago

Dexamthsone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dexamethasone1 trial

References

Drug Info

Quick Facts

Related News